Recce Pharmaceuticals Ltd (FRA:R9Q)

Market Cap	82.11M +66.1%
Revenue (ttm)	553.65K -89.8%
Net Income	-17.19M
EPS	-0.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,000
Open	0.2560
Previous Close	0.2500
Day's Range	0.2560 - 0.2560
52-Week Range	0.1290 - 0.4500
Beta	n/a
RSI	44.96
Earnings Date	May 28, 2026

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. The company’s lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infect...

• Industry: Pharmaceutical Preparations
• Founded: 2007
• Country: Australia
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: R9Q

Financial Performance

In fiscal year 2025, Recce Pharmaceuticals's revenue was 7.51 million, an increase of 49.33% compared to the previous year's 5.03 million. Losses were -21.43 million, 21.3% more than in 2024.

Financial numbers in AUD